No Data
Baiyunshan (600332.SH): Cefdinir granules have received a pharmaceutical registration certificate.
On November 25, Gelonghui reported that baiyunshan ph (600332.SH) announced that its holding subsidiary, Guangzhou baiyunshan ph Tianxin Pharmaceutical Co., Ltd. (referred to as 'Tianxin Pharmaceutical'), received the pharmaceutical registration certificate approved and issued by the National Medical Products Administration for Cefdinir Granules (50mg). Cefdinir Granules belong to the third generation of cephalosporin antibiotics, which mainly exert their bactericidal effect by inhibiting the synthesis of bacterial cell walls, making it a broad-spectrum antibiotic that was approved for market launch in 2002 in china. It is suitable for the treatment of Staphylococcus, Streptococcus, Pneumococcus, Streptococcus dysgalactiae, and Propionibacterium that are sensitive to Cefdinir.
Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt Responsibly
China Approves Baiyunshan Pharma Unit's Supplementary Application for Traditional Chinese Drug
Baiyunshan (600332.SH): The subsidiary has received approval for the supplementary pharmaceutical application.
On November 21, Gelonghui reported that baiyunshan ph (600332.SH) announced that its subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd. (referred to as "Zhongyi Pharmaceutical"), received the "Notification of Approval for Supplementary Application of Pharmaceutical" issued by the National Medical Products Administration. Zhongyi Pharmaceutical submitted this pharmaceutical supplementary application to the National Medical Products Administration on October 22, 2024, and it was accepted on October 25, 2024. The compound cold remedy capsule is used for the symptoms of wind-heat cold, including fever, slight aversion to cold, body aches, dry mouth and thirst, nasal congestion with thick mucus, red and swollen throat, cough, and yellow thick phlegm. This pharmaceutical was originally produced by the company's subsidiary Guangzhou Baiyunshan Qixing.
The baiyunshan ph (600332.SH) subsidiary He J Gong Pharmaceutical Factory has obtained approval for the new production line and production scope.
baiyunshan ph (600332.SH) issued a notice that the company's subsidiary Guangzhou baiyunshan ph Pharmaceutical Group Co., Ltd. baiyun...
Baiyunshan (00874.HK) has had a shareholding reduction of 0.664 million shares by Norges Bank.
On November 20, Gelonghui reported that according to the latest equity disclosure information from the Stock Exchange, on November 14, 2024, baiyunshan ph (00874.HK) was reduced by Norges Bank in the market by 664,000 shares at an average price of 18.312 Hong Kong dollars per share, involving about 12.1592 million Hong Kong dollars. After the shareholding reduction, the latest number of shares held by Norges Bank is 14.935 million shares, and the shareholding ratio has decreased from 7.09% to 6.79%.
Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed DownNo Data
No Data
